CD20 inhib 
Welcome,         Profile    Billing    Logout  
 112 Companies  89 Products   89 Products   542 Diseases   1399 Trials   78651 News 
1794 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruxience (rituximab-pvvr) / Pfizer
DanNORMS, NCT04688788: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Active, not recruiting
3
600
Europe
Rituximab, Ruxience, Rixathon® or other biosimilar rituximab, Ocrelizumab, Ocrevus, Fexofenadine, Paracetamol, Methylprednisolone
Rigshospitalet, Denmark, Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, Kolding Sygehus, Gødstrup Hospital, Hvidovre University Hospital, Hospital of South West Jutland, Esbjerg, Denmark, GCP unit, Copenhagen University Hospital, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Hospital of Southern Jutland, Sønderborg, Denmark, Hospital of Central Denmark Region, Viborg, Denmark, Danske Regioner, Hospital of Southern Jutland, Aabenraa, Denmark, Sanquin Research & Blood Bank Divisions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
05/26
05/28
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
Arzerra (ofatumumab) / Novartis, Genmab
2017-003593-13: UK CLL Long Term Follow Up Study

Ongoing
4
800
Europe
Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab
University of Leeds, Napp Pharmaceuticals
Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04]
 
 
ChiCTR2400086835: Ofatumumab for the treatment of optic neuritis associated with neuromyelitis optica spectrum disorder

Recruiting
4
10
 
hypodermic injection(the individual group accept 20mg ofatumumab subcutaneously once a week in week 0, week 2 of the first month, and the B lymphocyte subsets were detected every month after that. Supplementary injection was performed when CD19+B lymphocytes close to the target value 1%)
Chinese PLA General Hospital & Chinese PLA Medical School; Chinese PLA General Hospital & Chinese PLA Medical School, self-financing
optic neuritis associated with neuromyelitis optica spectrum disorder
 
 
2009-012518-39: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy

Ongoing
3
60
Europe
OFATUMUMAB, GSK1841157,
GlaxoSmithKline Research and Development, GlaxoSmithKline Research and Development Limited, GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GlaxoSmithKline S.A, , GlaxoSMithKline, GlaxoSmithKline
Subjects who are in CR or PR after 1 or 2 treatments for relapsed CLL
 
 
2013-002405-61: Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with Ofatumumab

 
3
80
Europe
Duvelisib, ARZERRA, Duvelisib, Ofatumumab, Ofatumumab
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
2013-003639-31: Study to assess the safety of the study drug IPI-145/Duvelisib or ofatumumab in leukemia patients

 
3
36
Europe
Duvelisib, ARZERRA, Duvelisib, L01XC10, OFATUMUMAB, OFATUMUMAB
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
RADIA, NCT06867991: Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Recruiting
3
200
RoW
Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
The First People's Hospital of Changzhou
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
11/26
11/27
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2012-001597-29: Tumor uptake of ofatumumab and rituximab, labeled with 89Zirconium, in patients with malignant lymphoma. Tumor opname van ofatumumab en rituximab, gelabeld met 89Zirconium bij patienten met lymfeklierkanker

Ongoing
2
45
Europe
rituximab-N-succinyl-desferal-zirconium-89, ofatumumab-N-succinyl-desferal-zirconium-89, 89Zr-rituximab, 89Zr-ofatumumab, Solution for injection/infusion
VU University Medical Center, VU University Medical Center, GlaxoSmithKline
Diffuse large B cell lymphoma (DLBCL), lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-002307-14: Phase II salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL). Traitement de phase II par Bendamustine, Ofatumumab et MethylPrednisolone (BOMP) dans les leucémies lymphoïdes chroniques B (LLC-B) en rechute.

Ongoing
2
115
Europe
LEVACT 2,5 mg/ml powder for infusion, Ofatumumab, GSK 1841157, Powder for infusion, Concentrate and solvent for solution for infusion, Chlorhydrate de bendamustine, Arzerra ®
Groupe Est Ouest des Leucémies et Autres Maladies du Sang, Groupe Est Ouest des Leucémies et Autres Maladies du Sang
relapsed B-cell chronic lymphocytic leukemia (B-CLL). LLC B, relapsed B-cell chronic lymphocytic leukemia (B-CLL). leucémies lymphoïdes chroniques B (LLC-B) en rechute, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie

Ongoing
2
73
Europe
Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra
Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline
Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04]
 
 
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
2
53
Europe, US
alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies
Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/15
05/27
2012-004998-53: Ofatumumab for the therapy of malignant lymphoproliferative disorder, called Waldenström’s macroglobulinemia (WM). Οφατουμουμάμπη για τη θεραπεία κακοήθους νεοπλασματικής διαταραχής, που ονομάζεται μακροσφαιριναιμία Waldenström.

Ongoing
2
39
Europe
Ofatumumab, GSK1841157, Arzerra, Arzerra
National and Kapodistrian University of Athens, National and Kapodistrian University of Athens
Relapsed or refractory Waldenström’s Macroglobulinemia. Υποτροπιάζουσα ή ανθεκτική μακροσφαιριναιμία Waldenström.
 
 
2010-022681-27: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Ongoing
2
30
Europe
ofatumumab, Arzerra,
University Hospital Brno
Patients with refractory/relapsed CLL
 
 
2009-017675-16: Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma

Ongoing
2
34
Europe
Ofatumumab, GSK1841157
Plymouth Hospitals NHS Trust
Relapsed or refractory Mantle Cell Lymphoma
 
 
2010-024389-23: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Ongoing
2
30
Europe
Ofatumumab, MabCampath®, GSK1841157, Arzerra, MabCampath®, Arzerra, MabCampath®
Department of Hematology, GlaxoSmithKlineAB
Chronic Lymphocytic Leukemia
 
 
CALGB-50904, NCT01286272: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Active, not recruiting
2
135
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Positron Emission Tomography with Radiolabeled Targeting Agent, Positron Emission Tomography with Radiolabeled Targeting Agents
National Cancer Institute (NCI)
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
05/17
03/25
NCT01145209: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Completed
2
32
US
Fludarabine Phosphate, Fludara, Ofatumumab, Arzerra, Cyclophosphamide, Cytoxan, Neosar
National Heart, Lung, and Blood Institute (NHLBI), University of Virginia, GlaxoSmithKline
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
10/17
09/23
NCI-2011-03562, NCT01527149: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed
2
37
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Roswell Park Cancer Institute, National Comprehensive Cancer Network
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
04/18
01/24
GELLC-7, NCT03280160 / 2016-004937-26: Protocol Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Active, not recruiting
2
84
Europe
Ibrutinib 140 MG Oral Capsule [Imbruvica], Ofatumumab
PETHEMA Foundation
Chronic Lymphocytic Leukemia
07/18
09/22
NCT01496976: Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Active, not recruiting
2
45
US
High Dose Methylprednisolone (HDMP), HDMP, Ofatumumab, Arzerra®, Lenalidomide, Revlimid®, IMiD® compound
H. Lee Moffitt Cancer Center and Research Institute, Novartis, Celgene Corporation
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/21
03/25
NCI-2014-01707, NCT02199184: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
2
14
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
02/23
02/23
NCT01243190: Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Completed
2
44
US
Ofatumumab, Arzerra
M.D. Anderson Cancer Center, GlaxoSmithKline
Chronic Lymphocytic Leukemia
03/23
03/23
NCT01437709: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Completed
2
30
US
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
09/23
09/23
NCT02135133: A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Checkmark CLL
Jun 2016 - Jun 2016: CLL
Completed
2
27
US
Idelalisib, GS1101, Ofatumumab, Arzerra
Dana-Farber Cancer Institute, Gilead Sciences, GlaxoSmithKline
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/20
10/20
NCT01258933: Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Terminated
2
4
US
Ofatumumab, Arzerra
M.D. Anderson Cancer Center, GlaxoSmithKline
Leukemia, Lymphoma
10/24
10/24
ChiCTR2400084937: Sequential Efgartigimod and Ofatumumab Therapy for Generalized Myasthenia Gravis

Completed
2
30
 
Patients in the experimental group receive Efgartigimod at a dose of 10mg/kg via intravenous infusion over 1 hour once a week for 4 consecutive weeks in the first month. On days 1, 7, and 14 of the second month, they receive a subcutaneous injection of 20mg of Ofatumumab as a loading dose, followed by maintenance subcutaneous injections of 20mg of Ofatumumab every 4 weeks thereafter.
Peking University People's Hospital; Peking University People's Hospital, The research was funded by the National Natural Science Foundation of China (Grant No. 81303013).
myasthenia gravis
 
 
NCT02388048 / 2015-000684-13: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Completed
2
19
Europe
Ibrutinib + ofatumumab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Lymphoblastic, Chronic
04/24
04/24
NCI-2018-01198, NCT03136146: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recruiting
2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Clofarabine, Clofarex, Clolar, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate Liposome, Marqibo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
08/25
08/26
NCI-2017-00596, NCT02877303: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Recruiting
2
80
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Laboratory Biomarker Analysis, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
11/26
11/26
NCT05504694: Ofatumumab in AQP4-IgG Seropositive NMOSD

Recruiting
1/2
5
RoW
Ofatumumab, Arzerra
Tang-Du Hospital, Henan Provincial People's Hospital
Neuromyelitis Optica Spectrum Disorder
06/24
12/24
ChiCTR2300076302: Effect of plasma exchange combined with Ofatumumab on B lymphocytes in patients with NMOSD

Not yet recruiting
1
20
 
Ofatumumab; Mycophenolate mofetil
Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Zhongguancun Precision Medicine Foundation
NMOSD
 
 
NCT06654817: Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris

Completed
N/A
38
RoW
Ofatumumab subcutaneous injection
Chao Ji
Pemphigus, Pemphigus Vulgaris (PV)
04/24
04/24
Rituxan (rituximab) / Roche
2006-005386-19: Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab

Ongoing
4
20
Europe
Solution for infusion, MabThera
Cliniques Universitaires Saint-Luc
Rheumatoid arthritis refractory to TNF blockers patients
 
 
2006-006154-97: HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkinﾒs Lymphoma in Adults

Ongoing
4
25
Europe
Powder for solution for injection, Tablet, Solution for infusion, Solution for injection, Powder for infusion*, Powder and solvent for solution for injection, Concentrate for solution for infusion, ENDOXAN BAXTER*EV 1FL 500MG, DELTACORTENE FORTE*10CPR 25MG, MABTHERA*EV 1FL 50ML 500MG, DECADRON*10CPR 0,5MG, VINCRISTINA TEVA*IV FL 1MG 1ML, HOLOXAN*EV 1FL 1G, METOTRESSATO TEVA*FL 1G 10ML, VEPESID*EV 1FL 100MG/5ML, VUMON*INFUS 1F 50MG/5ML, ELDISINE*INIET EV FL POLV 5MG, ARACYTIN*IV SC 1FL 500MG+F10ML, CAELYX*INFUS 1FL 2MG/ML 25ML
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
B-ALL, Burkitt and Burkitt likeand Non-Hodgkinﾒs Lymphoma in Adults
 
 
2008-000978-20: Influence de la plasmaphérèse sur la pharmacocinétique du rituximab chez des patients traités pour des pathologies auto immunes.

Ongoing
4
20
Europe
Solution for injection, MABTHERA
CHU Toulouse
Pathologies auto-immunes
 
 
ChiCTR-TRC-08000108: Clinical study of Mabthera (Rituximab)+chemotherapy for the treatment in non-Hodgkin's lymphoma (NHL)

Recruiting
4
150
 
EPOCH ;Chemo-treatment ;Chemo-treatment
Fujian Provincial Tumour Hospital; Level of the institution：, Self-supported
Non-Hodgkin's lymphoma (NHL)
 
 
ChiCTR-TNC-10000798: Rituximab in the treatment of severe lupus myelopathy: a prospective, open-label pilot trial

Completed
4
6
 
Rituximab (MabThera,500mg, intravenously weekly or biweekly for 2-3 times)
Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital; Level of the institution：, Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital
lupus myelopathy
 
 
ChiCTR-ONC-10001125: The clinical application of rituximabin in treatment of refractory nephrotic syndrome in children

Completed
4
30
 
rituximab 375mg/m2
Nanjing General hospital of Nanjing militray command; No.305, Zhongshan East Road, Xuanwu District, Nanjing, China, Self-finance
refractory nephrotic syndrome in children
 
 
2012-002535-28: Not applicable

Ongoing
4
180
Europe
MabThera, RoActemra, L01X CO2, L04AC07, Concentrate for solution for infusion, MabThera, RoActemra
Joint Research & Development Office (Barts and The London School of Medicine & Dentistry), Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, , Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, ECAM Clinical Academic Group Barts Health NHS Trust, Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2014-000859-91: Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde. Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde.

Not yet recruiting
4
100
Europe
Concentrate for solution for infusion, MABTHERA
CHRU de TOURS, CHRU de TOURS
Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab. Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab., Polyarthrite rhumatoïde (PR) Polyarthrite rhumatoïde (PR), Diseases [C] - Immune System Diseases [C20]
 
 
2015-001807-29: Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitis

Not yet recruiting
4
20
Europe
Rituximab, Concentrate for solution for injection, Rituximab
CHU de Saint-Etienne, THERADIAG
Granulomatosis with polyangiitis Microscopic polyangiitis granulomatose avec polyangéite (GPA) et la polyangéite microscopique (PAM), systemic vasculitis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
 
 
2015-000863-15: RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE + BIOLOGIC VERSUS METHOTREXATE, SALAZOPYRINE AND HYDROXYCHLOROQUINEIN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE

Not yet recruiting
4
286
Europe
L04AB01, Powder and solution for solution for injection, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Concentrate for solution for injection, Tablet, Powder and solvent for solution for injection, ENBREL, HUMIRA, REMICADE, ORENCIA, SIMPONI, CIMZIA, ROACTEMRA, MABTHERA, SALAZOPYRINE, IMETH, METOJECT, PLAQUENIL
Hôpitaux Universitaires de Strasbourg, Ministry of Health
RHEUMATOID ARTHRITIS, PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE, Diseases [C] - Immune System Diseases [C20]
 
 
2004-001199-37: A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy for Patients with Aggressive Non Hodgkin’s Lymphoma (NHL).

Ongoing
4
75
Europe
cyclophosphamide, Vincristine, Prednisone, Rituximab, Myocet, Myocet
(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas
Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.
 
 
2005-000674-43: AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:Clinical, radiological, synovial and immunological outcomes

Ongoing
4
15
Europe
Mabthera, N/A, Mabthera, Mabthera
University of Leeds
Rheumatoid Arthritis
 
 
2005-004582-41: Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis

Ongoing
4
15
Europe
Mabthera, Arava, Solu-Medrone 2mg, Rituximab, Leflunomide, Methylprednisolone, Mabthera, Arava, Solu-Medrone 2 Gram, Mabthera, Arava, Solu-Medrone 2 Gram
University of Leeds
Active Rheumatoid Arthritis
 
 
2005-005110-20: Tratamiento de primera línea del linfoma difuso de célula grande B (LDCGB) con quimioterapia a dosis densas e inmunoterapia (R-CHOP/14) en pacientes mayores de 65 años, y en menores de 65 años de riesgo bajoFirst-line treatment of diffuse large B-cell lymphoma (DLBCL) with dose-dense chemotherpahy and immunotherapy (R-CHOP/14) in patients older than 65 years and in low-risk patients younger than 65 years

Ongoing
4
139
Europe
Rituximab, Ciclofosfamida, Adriamicina (Doxorubicina), Vincristina, Prednisona,
GEL/TAMO (Grupo Cooperativo Español de Linfoma/Transplante Antólogo de Médula Ósea)
Linfoma difuso de célula grande B (LDCGB)Diffuse large B-cell lymphoma (DLBCL)
 
 
2007-003623-20: Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR).Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study).

Ongoing
4
20
Europe
Rituximab, Mabthera, Mabthera
Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona
Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide.
 
 
2008-006342-25: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia

Ongoing
4
218
Europe
Rituximab (MabThera), Fludarbine (Fludara Oral), Fludarabine (Fludara), Cyclophosphamide Tablets, Cyclophosphamide injection, Mitoxantrone, MabThera, Mitoxantrone, MabThera, Mitoxantrone
Leeds Teaching Hospitals NHS Trust
Chronic Lymphocytic Leukaemia
 
 
2009-010998-20: Attenuated dose Rituximab with ChemoTherapy In CLL:A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) tocompare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)

Ongoing
4
206
Europe
Rituximab (MabThera), Fludarabine (Fludara Oral), Cyclophosphamide Tablets, Fludarabine (Fludara), Mitoxantrone, Rituximab (MabThera or Rituxan) (Reduced dose), Cyclophosphamide injection, MabThera, Mitoxantrone, MabThera, Mitoxantrone
Leeds Teaching Hospitals NHS Trust
Chronic Lymphocytic Leukaemia
 
 
2009-010955-29: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.

Ongoing
4
90
Europe
MabThera 500 mg (10mg/ml), MabThera 500 mg (10mg/ml)
Division of Clinically Immunology and Rheumatology, AMC
Pre-clinical RA patients with a high risk on developing the disease.
 
 
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis.

Ongoing
4
33
Europe
Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept)
Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
Rheumatoid arthritis
 
 
2009-016848-39: Evaluation en TEP des modifications du métabolisme cérébral induit par la chimiothérapie RCHOP chez des malades porteurs de lymphome.

Ongoing
4
15
Europe
GLUCOTEP, GLUCOTEP
CHU Toulouse
lymphome
 
 
2009-016789-10: Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab

Ongoing
4
90
Europe
Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine, Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine
Div KIR AMC
To assess the efficacy of A/H1N1 vaccination in patients treated with rituximab therapy
 
 
2010-020499-50`ACTRN12620000506998: Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody.An investigator-led, industry supported, multicentre, open-label, single treatment arm, prospective clinical trial.

Ongoing
4
46
Europe
rituximab, MabThera, MabThera
South Tees Hospitals NHS Foundation Trust, Alzheimer's Association
Alzheimer's disease, Mild Cognitive Impairment
 
 
2011-000905-30: CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY) ENSAYO CLÍNICO DE TENOFOVIR EN PROFILAXIS DE PACIENTES HEMATOLÓGICOS ANTI-HBc POSITIVO Y AgHBs NEGATIVO EN TRATAMIENTO CON RITUXIMAB (Estudio PREBLIN)

Ongoing
4
98
Europe
VIREAD, J05AF07, VIREAD, VIREAD
Rafael Esteban Mur, Gilead Sciences, Inc.
CHRONIC HEPATITIS B HEPATITIS CRÓNICA B
 
 
2011-000899-33: Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatment

Ongoing
4
50
Europe
mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon
Department of Endocrinology, Sahlgrenska University Hospital
Thyroid associated opthalmopathy
 
 
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie.

Ongoing
4
140
Europe
Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip)
St. Antonius Hospital, St. Antonius Hospital
multiple myeloma multipel myeloom
 
 
2016-002908-15: REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritis REDO studie: Onderzoek naar de effecten van lagere doseringen rituximab bij patiënten met reumatoïde artritis

Ongoing
4
140
Europe
Infusion, MabThera
Sint Maartenskliniek, Menzis, CZ
Rheumatoid arthritis Reumatoïde artritis, Rheumatoid arthritis, chronic inflammation of the joints Reumatoïde artritis, reuma, chronische gewrichtsontsteking, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-000833-64: Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde.

Not yet recruiting
4
110
Europe
Powder for concentrate for solution for injection/infusion, Solution for infusion, ORENCIA, MABTHERA, ROACTEMRA
CHU Amiens-Picardie
Rheumatoid arthritis polyarthrite rhumatoïde, Rheumatoid arthritis Polyarthrite rhumatoïde, Diseases [C] - Immune System Diseases [C20]
 
 
2017-001619-35: Rituximab as first-line therapy in lupus nephritis Rituximab en première ligne thérapeutique dans la néphrite lupique

Ongoing
4
5
Europe
Solution for injection/infusion, Mabthera
Cliniques Universitaires Saint-lus, Université catholique de Louvain, Cliniques Universitaires saint-Luc, Université catholique de Louvain
Lupus Nephritis Néphrite Lupique, Lupus Nephritis Néphrite Lupique, Diseases [C] - Immune System Diseases [C20]
 
 
ChiCTR-IPR-15006457: A prospective, multicenter, randomized,double-blind study of mabthera adjuvant therapy in treating ocular adnexal lymphomas

Not yet recruiting
4
140
 
Local radiotherapy and mabthera ;Local radiotherapy and placebo ;CHOP chemotherapy and mabthera ;CHOP chemotherapy and local radiotherapy
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Level of the institution：, Public science and technology research funds project
Ocular adnexal lymphoma
 
 
2017-001117-86: Elective rituximab in TTP

Ongoing
4
52
Europe
Mabthera, Concentrate for solution for infusion, Mabthera
University College London, Answering TTP Foundation
Acquired thrombotic thrombocytopenic purpura, TTP, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR-OPC-16008628: Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma

Recruiting
4
20
 
Chidamide with Rituximab
Qilu Hospital， Shandong University; Level of the institution：, none
Germinal center subtype of Diffuse Large B Cell Lymphoma
 
 
ChiCTR1800020142: The clinical study on the efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in the treatment of diffuse large B-cell lymphoma

Recruiting
4
300
 
PLD 25 mg/ m2，iv，d1，cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, up to 2 mg, or vindesine 3 mg/m2, intravenously (iv.) all on day 1; and prednisone 100 mg orally on days 1 to 5, with or without rituximab 375 mg/m2, iv. on day 0, administered every 21 days (n=304) for six or eight cycle
Beijing Cancer Hospital; Beijing Cancer Hospital, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
diffuse large B-cell lymphoma
 
 
ChiCTR-OPC-16010056: The efficacy and safety of R-EPOCH and R-CHOP regimen for patients with AIDS associated CD20+ diffuse large B lymphoma

Recruiting
4
50
 
R-EPOCH regimen treatment ;R-CHOP regimen treatment
Shanghai Public Health Clinical Center; 上海市金山区漕廊公路2901号, Medical Science Support Program by Shanghai Science and Technology Committee
AIDS-associated CD20+ diffuse large B lymphoma
 
 
2018-003588-69: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis

Not yet recruiting
4
44
Europe
Cyclophosphamide, 5009111000001105, Powder for infusion, Cyclophosphamide
Leiden University Medical Center, LUMC leiden
ANCA associated vasculitis ANCA geassocieerde vasculitis, Small vessel vasculitis kleine vaten vasculitis, Diseases [C] - Immune System Diseases [C20]
 
 
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment

Not yet recruiting
4
84
Europe
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara
Reade, ZonMw
rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
LoVAS, NCT02198248: Low-dose Glucocorticoid Vasculitis Induction Study

Active, not recruiting
4
140
Japan
Rituximab, Rituxan, Glucocorticoids, Predonine, Prednisolone
Chiba University
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
12/19
06/21
ChiCTR-IPR-16008631: A randomized controlled study of comparing the efficacy and safety of Pegylated liposmal doxorubicin, Epirubicin and Doxorubicin in Diffuse large B cell lymphoma

Not yet recruiting
4
225
 
R-CDOP protocol ;R-CEOP protocol ;R-CHOP protocol
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing
Diffuse large B cell lymphoma
 
 
NCT02378298: Rituximab (RTX) Therapy in Patients With Active TAO

Completed
4
38
Europe
Rituximab, Mabthera, Rituxan, Zytux, L01XC02, Iv Methylprednisolone, Solumedrol, peroral methylprednisolone and Methotrexate, Prednisolone
Göteborg University, Sahlgrenska University Hospital
Ophthalmopathy, Thyroid-Associated
09/19
02/20
ChiCTR1800014960: Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study

Recruiting
4
30
 
Rituximab
Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
EBV Infection
 
 
2020-000484-23: Evaluation of the particular characteristics of patients with kidney diseases that could affect the behavior of rituximab in their organism. Investigación de las variables de pacientes con enfermedades del riñón que podrían afectar al comportamiento de rituximab en su organismo.

Ongoing
4
35
Europe
RITUXIMAB, Concentrate for solution for infusion, Rixathon
Vall d'Hebron Institute of Research, None
KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.) ENFERMEDADES RENALES CON AFECTACIÓN GLOMERULAR PRIMARIA(glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.), Diseases affecting the kidney affceting the glomeruli related with altered immune response. Enfermedades renales que afectan a los glomerulos y están relacionadas con alteraciones del sistema inmune., Body processes [G] - Immune system processes [G12]
 
 
ChiCTR1800020022: A multicenter, One-arm, Open, Prospective study for Low-dose Lenalidomide plus Rituximab (Laili) Regimen in the treatment of Elderly or Relapsed/Refractory B-cell non-Hodgkin's Lymphoma

Not yet recruiting
4
100
 
low dose of lenalidomide and rituximab
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, self-financed
B-cell non-Hodgkin's lymphoma
 
 
2020-002507-19: Research into administration of lower dosed rituximab with an injection Onderzoek naar het toedienen van lagere doseringen rituximab via een injectie

Not yet recruiting
4
36
Europe
rituximab, Solution for injection, Concentrate for solution for infusion, MabThera, Rixathon
Sint Maartenskliniek, Sint Maartenskliniek
rheumatoid arthritis reumatoïde artritis, rheumatic disease reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
ReMIND, NCT01095172 / 2009-017066-23: RituxiMab INDuction in Renal Transplantation

Checkmark BTS 2016: ReMIND
Mar 2016 - Mar 2016: BTS 2016: ReMIND
Active, not recruiting
4
100
Europe
Rituximab, Mabthera, Tacrolimus, Advagraf, Adoport, Prograf, Mycophenylate mofetil, MMF, Cellcept, Hydrocortisone, Prednisolone
Guy's and St Thomas' NHS Foundation Trust, Astellas Pharma Europe Ltd.
Function of Renal Transplant
10/20
10/22
ChiCTR-IPR-16008527: Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study

Completed
4
180
 
oral CsA and glucosteroid ;intravenous RTX ;Intravenous cyclophosphamide and glucosteroid
Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine; Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine, Multi-center research funding of Shanghai Jiaotong University School of Medicine
Membranous nephropathy
 
 
ChiCTR1900020916: A Clinical study for low dose Dectabine + R-CHOP treat diffuse large B cells lymphoma

Recruiting
4
20
 
low dose Dac+R-CHOP ;R-CHOP
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Anhui province department of finance appropriation
Diffuse Large B Cells Lymphoma
 
 
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie).

Ongoing
4
270
Europe
COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sint Maartenskliniek, Sint Maartenskliniek
Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
ChiCTR2000035408: A randomized controlled study for rituximab in first-line treatment of newly diagnosed immune thrombocytopenia

Recruiting
4
60
 
Rituximab (Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29). ;Rituximab (Hanrikang) 100mg/ time once a week, administered 4 times (day 8, 15, 22 and 29). ;high-dose dexamethasone (HD-DXM), 40mg/d, iv for 4 days (day 1 to day 4), every 15 days, 2 to 4 cycles, until CR or the end of the study.
Henan Cancer Hospital; Henan Cancer Hospital, Jiangsu fosun pharmaceutical sales co. LTD
Idiopathic Thrombocytopenic Purpura
 
 
NCT04542629: Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

Not yet recruiting
4
140
NA
RiTUXimab Injection [Rituxan], KETOGENIC DIET, TRACE ELEMENTS, CORTICOSTEROID INJECTION
Assiut University
Refractory Epilepsy
08/21
08/22
ChiCTR1800017001: Precision Medicine Study about Drug Effect and Adverse Reaction of Rituximab in lymphonma Treatment Based on Metabonomics, Pharmacogenomics and Gut Microbiota.

Recruiting
4
200
 
none
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, National Natural Science Foundation of China (81730103,81573507), Hospital Pharmacy Fundation of Guangdong
B cell lymphoma
 
 
ChiCTR1900026380: Rituximab plus Lenalidomide in elderly untreated patients with DLBCL

Recruiting
4
60
 
Rituximab plus Lenalidomide
Anhui Provincial Cance Hospital; Anhui Provincial Cance Hospital, Self-collected
DLBCL
 
 
ChiCTR2000033540: Prospective Randomized Trial on Efficacy of Rituximab Combined Therapy and Supportive Therapy on Early-Stage Non-Nephrotic Primary Membranous Nephropathy

Recruiting
4
38
 
Rituximab 600mg iv, and supportive treatment ;Supportive treatment according to KDIGO guideline
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Self-supporting
Membranous Nephropathy
 
 
MAINTANCAVAS, NCT02749292: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

Terminated
4
115
US
Rituximab, Rituxan
Massachusetts General Hospital
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
01/22
01/22
NCT04518475: Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Recruiting
4
224
RoW
eltrombopag combining rituximab, TPO-R agonist & anti-CD20 antibody, eltrombopag, TPO-R agonist
Institute of Hematology & Blood Diseases Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Nantong University
Primary Immune Thrombocytopenia (ITP)
02/22
08/22
NCT05191225: Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

Recruiting
4
48
Europe
RiTUXimab Injection [Truxima]
Laida Cuevas Palomares
Non-Hodgkin's Lymphoma
03/22
12/22
ChiCTR2000040799: Prospective study of rituximab combined with low-dose hormone in the treatment of idiopathic membranous nephropathy

Recruiting
4
50
 
Rituximab
The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, self-raised
idiopathic membranous nephropathy
 
 
ChiCTR2000033337: R-BAC regimen in the treatment of relapsed and refractory diffuse large B-cell lymphoma

Not yet recruiting
4
50
 
Rituximab, Bendamustine combined with Cytarabine
Xiangya Second Hospital of Central South University; Xiangya Second Hospital of Central South University, Self-raised
Relapsed and refractory diffuse large B-cell lymphoma
 
 
ChiCTR2000036318: A prospective phase II multicenter clinical study of rituximab combined with local radiotherapy in the treatment of newly diagnosed early mucosa-associated lymphoid tissue lymphoma

Not yet recruiting
4
60
 
rituximab combined with local radiotherapy
Anhui Provincial Cance Hospital; Level of the institution：, Self-collected
mucosa-associated lymphoid tissue lymphoma
 
 
ChiCTR2300070327: Efficacy of novle prednisone-premedication R-CHOP protocol vs. standard R-CHOP regimen in the prevention of rituximab-related reactions in newly-diagnosed diffuse large B cell lymphoma: A multicenter randomized controlled study

Completed
4
88
 
prednisone-premedication R-CHOP protocol ;standard R-CHOP regimen
Jiujiang University Affiliated Hospital; Jiujiang University Affiliated Hospital, None
diffuse large B cell lymphoma
 
 
rituximab treatment for MN with T2DM, ChiCTR2000032523: Efficacy and safety of rituximab in the treatment of primary membranous nephropathy with type 2 diabetes mellitus: a single-center randomized controlled trial.

Not yet recruiting
4
80
 
rituximab ;tacrolimus
Xinqiao Hospital; Xinqiao Hospital, The science and technology innovation ability enhancement special project of The Army Medical University
membranous nephropathy
 
 
ChiCTR1900025744: Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial

Recruiting
4
60
 
Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg) ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750～3000mg/day)
The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The General Hospital of Chinese Peoples Liberation Army, funded by the National Natural Science Fundation of China (NO.81870662)
neuromyelitis optica spectrum disorder （NMOSD）
 
 
NCT02752815: Reduced Chemotherapy in Low Risk DLBCL

Active, not recruiting
4
290
RoW
Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone
Ruijin Hospital
Diffuse Large B-cell Lymphoma
10/22
12/24
ChiCTR2000039456: A single arm and prospective clinical trial of zanubrutinib plus R-CHOP in untreated double expression diffuse large B-Cell Lymphoma with international prognostic index equal or greater than 2 scores

Recruiting
4
49
 
zanubrutinib plus R-CHOP
West China Hospital, Sichuan University; West China Hospital, Baiji Shenzhou Biotechnology Co., Ltd
double expressing diffuse large B-cell lymphoma
 
 
ChiCTR1900026382: Low dose rituximab driven by B cell count for nephrotic syndrome: a multi-center prospective cohort study

Completed
4
105
 
Rituximab
Jiangsu Province People's Hospital; Jiangsu Province People's Hospital, Jiangsu Province Kidney Disease Clinical Research Center program (BL 20100080)
nephrotic syndrome
 
 
ChiCTR2000030603: A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for glucocorticoid-dependent immune thrombocytopenia

Recruiting
4
390
 
treat with glucocorticoid ;treat with eltrombopag ;treat with rituximab ;treat with splenectomy ;treat with azathioprine ;treat with cyclosporine
The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University
Primary Immune Thrombocytopenia
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruxience (rituximab-pvvr) / Pfizer
DanNORMS, NCT04688788: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Active, not recruiting
3
600
Europe
Rituximab, Ruxience, Rixathon® or other biosimilar rituximab, Ocrelizumab, Ocrevus, Fexofenadine, Paracetamol, Methylprednisolone
Rigshospitalet, Denmark, Odense University Hospital, Aarhus University Hospital, Aalborg University Hospital, Herlev Hospital, Hillerod Hospital, Denmark, Kolding Sygehus, Gødstrup Hospital, Hvidovre University Hospital, Hospital of South West Jutland, Esbjerg, Denmark, GCP unit, Copenhagen University Hospital, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Hospital of Southern Jutland, Sønderborg, Denmark, Hospital of Central Denmark Region, Viborg, Denmark, Danske Regioner, Hospital of Southern Jutland, Aabenraa, Denmark, Sanquin Research & Blood Bank Divisions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
05/26
05/28
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
Arzerra (ofatumumab) / Novartis, Genmab
2017-003593-13: UK CLL Long Term Follow Up Study

Ongoing
4
800
Europe
Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab
University of Leeds, Napp Pharmaceuticals
Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04]
 
 
ChiCTR2400086835: Ofatumumab for the treatment of optic neuritis associated with neuromyelitis optica spectrum disorder

Recruiting
4
10
 
hypodermic injection(the individual group accept 20mg ofatumumab subcutaneously once a week in week 0, week 2 of the first month, and the B lymphocyte subsets were detected every month after that. Supplementary injection was performed when CD19+B lymphocytes close to the target value 1%)
Chinese PLA General Hospital & Chinese PLA Medical School; Chinese PLA General Hospital & Chinese PLA Medical School, self-financing
optic neuritis associated with neuromyelitis optica spectrum disorder
 
 
2009-012518-39: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy

Ongoing
3
60
Europe
OFATUMUMAB, GSK1841157,
GlaxoSmithKline Research and Development, GlaxoSmithKline Research and Development Limited, GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GlaxoSmithKline S.A, , GlaxoSMithKline, GlaxoSmithKline
Subjects who are in CR or PR after 1 or 2 treatments for relapsed CLL
 
 
2013-002405-61: Study to assess the safety and efficacy of the study drug IPI-145/Duvelisib in Leukaemia patients compared with Ofatumumab

 
3
80
Europe
Duvelisib, ARZERRA, Duvelisib, Ofatumumab, Ofatumumab
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
2013-003639-31: Study to assess the safety of the study drug IPI-145/Duvelisib or ofatumumab in leukemia patients

 
3
36
Europe
Duvelisib, ARZERRA, Duvelisib, L01XC10, OFATUMUMAB, OFATUMUMAB
Infinity Pharmaceuticals, Inc, Infinity Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
 
 
RADIA, NCT06867991: Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Recruiting
3
200
RoW
Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy
The First People's Hospital of Changzhou
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
11/26
11/27
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2012-001597-29: Tumor uptake of ofatumumab and rituximab, labeled with 89Zirconium, in patients with malignant lymphoma. Tumor opname van ofatumumab en rituximab, gelabeld met 89Zirconium bij patienten met lymfeklierkanker

Ongoing
2
45
Europe
rituximab-N-succinyl-desferal-zirconium-89, ofatumumab-N-succinyl-desferal-zirconium-89, 89Zr-rituximab, 89Zr-ofatumumab, Solution for injection/infusion
VU University Medical Center, VU University Medical Center, GlaxoSmithKline
Diffuse large B cell lymphoma (DLBCL), lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2011-002307-14: Phase II salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL). Traitement de phase II par Bendamustine, Ofatumumab et MethylPrednisolone (BOMP) dans les leucémies lymphoïdes chroniques B (LLC-B) en rechute.

Ongoing
2
115
Europe
LEVACT 2,5 mg/ml powder for infusion, Ofatumumab, GSK 1841157, Powder for infusion, Concentrate and solvent for solution for infusion, Chlorhydrate de bendamustine, Arzerra ®
Groupe Est Ouest des Leucémies et Autres Maladies du Sang, Groupe Est Ouest des Leucémies et Autres Maladies du Sang
relapsed B-cell chronic lymphocytic leukemia (B-CLL). LLC B, relapsed B-cell chronic lymphocytic leukemia (B-CLL). leucémies lymphoïdes chroniques B (LLC-B) en rechute, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie

Ongoing
2
73
Europe
Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra
Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline
Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04]
 
 
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
2
53
Europe, US
alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies
Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/15
05/27
2012-004998-53: Ofatumumab for the therapy of malignant lymphoproliferative disorder, called Waldenström’s macroglobulinemia (WM). Οφατουμουμάμπη για τη θεραπεία κακοήθους νεοπλασματικής διαταραχής, που ονομάζεται μακροσφαιριναιμία Waldenström.

Ongoing
2
39
Europe
Ofatumumab, GSK1841157, Arzerra, Arzerra
National and Kapodistrian University of Athens, National and Kapodistrian University of Athens
Relapsed or refractory Waldenström’s Macroglobulinemia. Υποτροπιάζουσα ή ανθεκτική μακροσφαιριναιμία Waldenström.
 
 
2010-022681-27: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

Ongoing
2
30
Europe
ofatumumab, Arzerra,
University Hospital Brno
Patients with refractory/relapsed CLL
 
 
2009-017675-16: Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma

Ongoing
2
34
Europe
Ofatumumab, GSK1841157
Plymouth Hospitals NHS Trust
Relapsed or refractory Mantle Cell Lymphoma
 
 
2010-024389-23: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Ongoing
2
30
Europe
Ofatumumab, MabCampath®, GSK1841157, Arzerra, MabCampath®, Arzerra, MabCampath®
Department of Hematology, GlaxoSmithKlineAB
Chronic Lymphocytic Leukemia
 
 
CALGB-50904, NCT01286272: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Active, not recruiting
2
135
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Positron Emission Tomography with Radiolabeled Targeting Agent, Positron Emission Tomography with Radiolabeled Targeting Agents
National Cancer Institute (NCI)
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
05/17
03/25
NCT01145209: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Completed
2
32
US
Fludarabine Phosphate, Fludara, Ofatumumab, Arzerra, Cyclophosphamide, Cytoxan, Neosar
National Heart, Lung, and Blood Institute (NHLBI), University of Virginia, GlaxoSmithKline
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
10/17
09/23
NCI-2011-03562, NCT01527149: Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed
2
37
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Roswell Park Cancer Institute, National Comprehensive Cancer Network
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
04/18
01/24
GELLC-7, NCT03280160 / 2016-004937-26: Protocol Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Active, not recruiting
2
84
Europe
Ibrutinib 140 MG Oral Capsule [Imbruvica], Ofatumumab
PETHEMA Foundation
Chronic Lymphocytic Leukemia
07/18
09/22
NCT01496976: Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Active, not recruiting
2
45
US
High Dose Methylprednisolone (HDMP), HDMP, Ofatumumab, Arzerra®, Lenalidomide, Revlimid®, IMiD® compound
H. Lee Moffitt Cancer Center and Research Institute, Novartis, Celgene Corporation
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/21
03/25
NCI-2014-01707, NCT02199184: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed
2
14
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
02/23
02/23
NCT01243190: Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Completed
2
44
US
Ofatumumab, Arzerra
M.D. Anderson Cancer Center, GlaxoSmithKline
Chronic Lymphocytic Leukemia
03/23
03/23
NCT01437709: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Completed
2
30
US
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
09/23
09/23
NCT02135133: A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Checkmark CLL
Jun 2016 - Jun 2016: CLL
Completed
2
27
US
Idelalisib, GS1101, Ofatumumab, Arzerra
Dana-Farber Cancer Institute, Gilead Sciences, GlaxoSmithKline
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/20
10/20
NCT01258933: Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Terminated
2
4
US
Ofatumumab, Arzerra
M.D. Anderson Cancer Center, GlaxoSmithKline
Leukemia, Lymphoma
10/24
10/24
ChiCTR2400084937: Sequential Efgartigimod and Ofatumumab Therapy for Generalized Myasthenia Gravis

Completed
2
30
 
Patients in the experimental group receive Efgartigimod at a dose of 10mg/kg via intravenous infusion over 1 hour once a week for 4 consecutive weeks in the first month. On days 1, 7, and 14 of the second month, they receive a subcutaneous injection of 20mg of Ofatumumab as a loading dose, followed by maintenance subcutaneous injections of 20mg of Ofatumumab every 4 weeks thereafter.
Peking University People's Hospital; Peking University People's Hospital, The research was funded by the National Natural Science Foundation of China (Grant No. 81303013).
myasthenia gravis
 
 
NCT02388048 / 2015-000684-13: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Completed
2
19
Europe
Ibrutinib + ofatumumab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Lymphoblastic, Chronic
04/24
04/24
NCI-2018-01198, NCT03136146: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recruiting
2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Clofarabine, Clofarex, Clolar, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate Liposome, Marqibo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
08/25
08/26
NCI-2017-00596, NCT02877303: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Recruiting
2
80
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Laboratory Biomarker Analysis, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
11/26
11/26
NCT05504694: Ofatumumab in AQP4-IgG Seropositive NMOSD

Recruiting
1/2
5
RoW
Ofatumumab, Arzerra
Tang-Du Hospital, Henan Provincial People's Hospital
Neuromyelitis Optica Spectrum Disorder
06/24
12/24
ChiCTR2300076302: Effect of plasma exchange combined with Ofatumumab on B lymphocytes in patients with NMOSD

Not yet recruiting
1
20
 
Ofatumumab; Mycophenolate mofetil
Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Zhongguancun Precision Medicine Foundation
NMOSD
 
 
NCT06654817: Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris

Completed
N/A
38
RoW
Ofatumumab subcutaneous injection
Chao Ji
Pemphigus, Pemphigus Vulgaris (PV)
04/24
04/24
Rituxan (rituximab) / Roche
2006-005386-19: Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab

Ongoing
4
20
Europe
Solution for infusion, MabThera
Cliniques Universitaires Saint-Luc
Rheumatoid arthritis refractory to TNF blockers patients
 
 
2006-006154-97: HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkinﾒs Lymphoma in Adults

Ongoing
4
25
Europe
Powder for solution for injection, Tablet, Solution for infusion, Solution for injection, Powder for infusion*, Powder and solvent for solution for injection, Concentrate for solution for infusion, ENDOXAN BAXTER*EV 1FL 500MG, DELTACORTENE FORTE*10CPR 25MG, MABTHERA*EV 1FL 50ML 500MG, DECADRON*10CPR 0,5MG, VINCRISTINA TEVA*IV FL 1MG 1ML, HOLOXAN*EV 1FL 1G, METOTRESSATO TEVA*FL 1G 10ML, VEPESID*EV 1FL 100MG/5ML, VUMON*INFUS 1F 50MG/5ML, ELDISINE*INIET EV FL POLV 5MG, ARACYTIN*IV SC 1FL 500MG+F10ML, CAELYX*INFUS 1FL 2MG/ML 25ML
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
B-ALL, Burkitt and Burkitt likeand Non-Hodgkinﾒs Lymphoma in Adults
 
 
2008-000978-20: Influence de la plasmaphérèse sur la pharmacocinétique du rituximab chez des patients traités pour des pathologies auto immunes.

Ongoing
4
20
Europe
Solution for injection, MABTHERA
CHU Toulouse
Pathologies auto-immunes
 
 
ChiCTR-TRC-08000108: Clinical study of Mabthera (Rituximab)+chemotherapy for the treatment in non-Hodgkin's lymphoma (NHL)

Recruiting
4
150
 
EPOCH ;Chemo-treatment ;Chemo-treatment
Fujian Provincial Tumour Hospital; Level of the institution：, Self-supported
Non-Hodgkin's lymphoma (NHL)
 
 
ChiCTR-TNC-10000798: Rituximab in the treatment of severe lupus myelopathy: a prospective, open-label pilot trial

Completed
4
6
 
Rituximab (MabThera,500mg, intravenously weekly or biweekly for 2-3 times)
Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital; Level of the institution：, Shanghai JiaoTong University School of Medicine Affiliated Renji Hospital
lupus myelopathy
 
 
ChiCTR-ONC-10001125: The clinical application of rituximabin in treatment of refractory nephrotic syndrome in children

Completed
4
30
 
rituximab 375mg/m2
Nanjing General hospital of Nanjing militray command; No.305, Zhongshan East Road, Xuanwu District, Nanjing, China, Self-finance
refractory nephrotic syndrome in children
 
 
2012-002535-28: Not applicable

Ongoing
4
180
Europe
MabThera, RoActemra, L01X CO2, L04AC07, Concentrate for solution for infusion, MabThera, RoActemra
Joint Research & Development Office (Barts and The London School of Medicine & Dentistry), Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, , Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London, ECAM Clinical Academic Group Barts Health NHS Trust, Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
Rheumatoid Arthritis, Rheumatoid Arthritis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2014-000859-91: Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde. Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde.

Not yet recruiting
4
100
Europe
Concentrate for solution for infusion, MABTHERA
CHRU de TOURS, CHRU de TOURS
Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab. Cette étude portera donc sur une population de patients atteints de polyarthrite rhumatoïde (PR) actives et ayant présenté un échec ou une contre-indication à au moins un anti-TNFα, et n’ayant jamais reçu de rituximab., Polyarthrite rhumatoïde (PR) Polyarthrite rhumatoïde (PR), Diseases [C] - Immune System Diseases [C20]
 
 
2015-001807-29: Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitis

Not yet recruiting
4
20
Europe
Rituximab, Concentrate for solution for injection, Rituximab
CHU de Saint-Etienne, THERADIAG
Granulomatosis with polyangiitis Microscopic polyangiitis granulomatose avec polyangéite (GPA) et la polyangéite microscopique (PAM), systemic vasculitis, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
 
 
2015-000863-15: RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE + BIOLOGIC VERSUS METHOTREXATE, SALAZOPYRINE AND HYDROXYCHLOROQUINEIN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE

Not yet recruiting
4
286
Europe
L04AB01, Powder and solution for solution for injection, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Concentrate for solution for injection, Tablet, Powder and solvent for solution for injection, ENBREL, HUMIRA, REMICADE, ORENCIA, SIMPONI, CIMZIA, ROACTEMRA, MABTHERA, SALAZOPYRINE, IMETH, METOJECT, PLAQUENIL
Hôpitaux Universitaires de Strasbourg, Ministry of Health
RHEUMATOID ARTHRITIS, PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE, Diseases [C] - Immune System Diseases [C20]
 
 
2004-001199-37: A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy for Patients with Aggressive Non Hodgkin’s Lymphoma (NHL).

Ongoing
4
75
Europe
cyclophosphamide, Vincristine, Prednisone, Rituximab, Myocet, Myocet
(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas
Dose-dense modified R-CHOP regimen (R-COMP) in patients with aggressive NHL.
 
 
2005-000674-43: AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:Clinical, radiological, synovial and immunological outcomes

Ongoing
4
15
Europe
Mabthera, N/A, Mabthera, Mabthera
University of Leeds
Rheumatoid Arthritis
 
 
2005-004582-41: Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis

Ongoing
4
15
Europe
Mabthera, Arava, Solu-Medrone 2mg, Rituximab, Leflunomide, Methylprednisolone, Mabthera, Arava, Solu-Medrone 2 Gram, Mabthera, Arava, Solu-Medrone 2 Gram
University of Leeds
Active Rheumatoid Arthritis
 
 
2005-005110-20: Tratamiento de primera línea del linfoma difuso de célula grande B (LDCGB) con quimioterapia a dosis densas e inmunoterapia (R-CHOP/14) en pacientes mayores de 65 años, y en menores de 65 años de riesgo bajoFirst-line treatment of diffuse large B-cell lymphoma (DLBCL) with dose-dense chemotherpahy and immunotherapy (R-CHOP/14) in patients older than 65 years and in low-risk patients younger than 65 years

Ongoing
4
139
Europe
Rituximab, Ciclofosfamida, Adriamicina (Doxorubicina), Vincristina, Prednisona,
GEL/TAMO (Grupo Cooperativo Español de Linfoma/Transplante Antólogo de Médula Ósea)
Linfoma difuso de célula grande B (LDCGB)Diffuse large B-cell lymphoma (DLBCL)
 
 
2007-003623-20: Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR).Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study).

Ongoing
4
20
Europe
Rituximab, Mabthera, Mabthera
Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona
Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide.
 
 
2008-006342-25: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia

Ongoing
4
218
Europe
Rituximab (MabThera), Fludarbine (Fludara Oral), Fludarabine (Fludara), Cyclophosphamide Tablets, Cyclophosphamide injection, Mitoxantrone, MabThera, Mitoxantrone, MabThera, Mitoxantrone
Leeds Teaching Hospitals NHS Trust
Chronic Lymphocytic Leukaemia
 
 
2009-010998-20: Attenuated dose Rituximab with ChemoTherapy In CLL:A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) tocompare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)

Ongoing
4
206
Europe
Rituximab (MabThera), Fludarabine (Fludara Oral), Cyclophosphamide Tablets, Fludarabine (Fludara), Mitoxantrone, Rituximab (MabThera or Rituxan) (Reduced dose), Cyclophosphamide injection, MabThera, Mitoxantrone, MabThera, Mitoxantrone
Leeds Teaching Hospitals NHS Trust
Chronic Lymphocytic Leukaemia
 
 
2009-010955-29: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.

Ongoing
4
90
Europe
MabThera 500 mg (10mg/ml), MabThera 500 mg (10mg/ml)
Division of Clinically Immunology and Rheumatology, AMC
Pre-clinical RA patients with a high risk on developing the disease.
 
 
2008-005450-20: The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis.

Ongoing
4
33
Europe
Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept), Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept), Mabthera (rituximab), Orencia (abatacept)
Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
Rheumatoid arthritis
 
 
2009-016848-39: Evaluation en TEP des modifications du métabolisme cérébral induit par la chimiothérapie RCHOP chez des malades porteurs de lymphome.

Ongoing
4
15
Europe
GLUCOTEP, GLUCOTEP
CHU Toulouse
lymphome
 
 
2009-016789-10: Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab

Ongoing
4
90
Europe
Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine, Focetria pandemic influenza vaccine, Pandemrix, Pandemic influenza vaccine
Div KIR AMC
To assess the efficacy of A/H1N1 vaccination in patients treated with rituximab therapy
 
 
2010-020499-50`ACTRN12620000506998: Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody.An investigator-led, industry supported, multicentre, open-label, single treatment arm, prospective clinical trial.

Ongoing
4
46
Europe
rituximab, MabThera, MabThera
South Tees Hospitals NHS Foundation Trust, Alzheimer's Association
Alzheimer's disease, Mild Cognitive Impairment
 
 
2011-000905-30: CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY) ENSAYO CLÍNICO DE TENOFOVIR EN PROFILAXIS DE PACIENTES HEMATOLÓGICOS ANTI-HBc POSITIVO Y AgHBs NEGATIVO EN TRATAMIENTO CON RITUXIMAB (Estudio PREBLIN)

Ongoing
4
98
Europe
VIREAD, J05AF07, VIREAD, VIREAD
Rafael Esteban Mur, Gilead Sciences, Inc.
CHRONIC HEPATITIS B HEPATITIS CRÓNICA B
 
 
2011-000899-33: Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatment

Ongoing
4
50
Europe
mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon, Mabthera, metotrexate, Solu-Medrol, Prednisolon
Department of Endocrinology, Sahlgrenska University Hospital
Thyroid associated opthalmopathy
 
 
2012-005713-39: Reponse to vaccination in patients with bonemarrowcancer who are treated with chemotherapy. Respons op vaccinatie bij patienten met beenmergkanker die behandeld worden met chemotherapie.

Ongoing
4
140
Europe
Prevnar 13, Influvac or Vaxigrip, RVG 25853, Prevnar 13, Influenza vaccine (Influvac or Vaxigrip), Prevnar 13, Influenza vaccine (Influvac or Vaxigrip)
St. Antonius Hospital, St. Antonius Hospital
multiple myeloma multipel myeloom
 
 
2016-002908-15: REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritis REDO studie: Onderzoek naar de effecten van lagere doseringen rituximab bij patiënten met reumatoïde artritis

Ongoing
4
140
Europe
Infusion, MabThera
Sint Maartenskliniek, Menzis, CZ
Rheumatoid arthritis Reumatoïde artritis, Rheumatoid arthritis, chronic inflammation of the joints Reumatoïde artritis, reuma, chronische gewrichtsontsteking, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2015-000833-64: Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde.

Not yet recruiting
4
110
Europe
Powder for concentrate for solution for injection/infusion, Solution for infusion, ORENCIA, MABTHERA, ROACTEMRA
CHU Amiens-Picardie
Rheumatoid arthritis polyarthrite rhumatoïde, Rheumatoid arthritis Polyarthrite rhumatoïde, Diseases [C] - Immune System Diseases [C20]
 
 
2017-001619-35: Rituximab as first-line therapy in lupus nephritis Rituximab en première ligne thérapeutique dans la néphrite lupique

Ongoing
4
5
Europe
Solution for injection/infusion, Mabthera
Cliniques Universitaires Saint-lus, Université catholique de Louvain, Cliniques Universitaires saint-Luc, Université catholique de Louvain
Lupus Nephritis Néphrite Lupique, Lupus Nephritis Néphrite Lupique, Diseases [C] - Immune System Diseases [C20]
 
 
ChiCTR-IPR-15006457: A prospective, multicenter, randomized,double-blind study of mabthera adjuvant therapy in treating ocular adnexal lymphomas

Not yet recruiting
4
140
 
Local radiotherapy and mabthera ;Local radiotherapy and placebo ;CHOP chemotherapy and mabthera ;CHOP chemotherapy and local radiotherapy
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Level of the institution：, Public science and technology research funds project
Ocular adnexal lymphoma
 
 
2017-001117-86: Elective rituximab in TTP

Ongoing
4
52
Europe
Mabthera, Concentrate for solution for infusion, Mabthera
University College London, Answering TTP Foundation
Acquired thrombotic thrombocytopenic purpura, TTP, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
ChiCTR-OPC-16008628: Chidamide with Rituximab for Relapsed/Refratory Germinal Center subtype of Diffuse Large B Cell Lymphoma

Recruiting
4
20
 
Chidamide with Rituximab
Qilu Hospital， Shandong University; Level of the institution：, none
Germinal center subtype of Diffuse Large B Cell Lymphoma
 
 
ChiCTR1800020142: The clinical study on the efficacy and safety of CDOP regimen with pegylated liposomal doxorubicin ± rituximab in the treatment of diffuse large B-cell lymphoma

Recruiting
4
300
 
PLD 25 mg/ m2，iv，d1，cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, up to 2 mg, or vindesine 3 mg/m2, intravenously (iv.) all on day 1; and prednisone 100 mg orally on days 1 to 5, with or without rituximab 375 mg/m2, iv. on day 0, administered every 21 days (n=304) for six or eight cycle
Beijing Cancer Hospital; Beijing Cancer Hospital, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
diffuse large B-cell lymphoma
 
 
ChiCTR-OPC-16010056: The efficacy and safety of R-EPOCH and R-CHOP regimen for patients with AIDS associated CD20+ diffuse large B lymphoma

Recruiting
4
50
 
R-EPOCH regimen treatment ;R-CHOP regimen treatment
Shanghai Public Health Clinical Center; 上海市金山区漕廊公路2901号, Medical Science Support Program by Shanghai Science and Technology Committee
AIDS-associated CD20+ diffuse large B lymphoma
 
 
2018-003588-69: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis

Not yet recruiting
4
44
Europe
Cyclophosphamide, 5009111000001105, Powder for infusion, Cyclophosphamide
Leiden University Medical Center, LUMC leiden
ANCA associated vasculitis ANCA geassocieerde vasculitis, Small vessel vasculitis kleine vaten vasculitis, Diseases [C] - Immune System Diseases [C20]
 
 
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment

Not yet recruiting
4
84
Europe
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara
Reade, ZonMw
rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 
LoVAS, NCT02198248: Low-dose Glucocorticoid Vasculitis Induction Study

Active, not recruiting
4
140
Japan
Rituximab, Rituxan, Glucocorticoids, Predonine, Prednisolone
Chiba University
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
12/19
06/21
ChiCTR-IPR-16008631: A randomized controlled study of comparing the efficacy and safety of Pegylated liposmal doxorubicin, Epirubicin and Doxorubicin in Diffuse large B cell lymphoma

Not yet recruiting
4
225
 
R-CDOP protocol ;R-CEOP protocol ;R-CHOP protocol
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-finacing
Diffuse large B cell lymphoma
 
 
NCT02378298: Rituximab (RTX) Therapy in Patients With Active TAO

Completed
4
38
Europe
Rituximab, Mabthera, Rituxan, Zytux, L01XC02, Iv Methylprednisolone, Solumedrol, peroral methylprednisolone and Methotrexate, Prednisolone
Göteborg University, Sahlgrenska University Hospital
Ophthalmopathy, Thyroid-Associated
09/19
02/20
ChiCTR1800014960: Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study

Recruiting
4
30
 
Rituximab
Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
EBV Infection
 
 
2020-000484-23: Evaluation of the particular characteristics of patients with kidney diseases that could affect the behavior of rituximab in their organism. Investigación de las variables de pacientes con enfermedades del riñón que podrían afectar al comportamiento de rituximab en su organismo.

Ongoing
4
35
Europe
RITUXIMAB, Concentrate for solution for infusion, Rixathon
Vall d'Hebron Institute of Research, None
KIDNEY DISEASES WITH PRIMARY GLOMERULAR AFFECTATION (glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.) ENFERMEDADES RENALES CON AFECTACIÓN GLOMERULAR PRIMARIA(glomerulonefritis membranosa, glomerulonefritis por cambios mínimos, vasculitis, glomerulosclerosis focal y segmentaria.), Diseases affecting the kidney affceting the glomeruli related with altered immune response. Enfermedades renales que afectan a los glomerulos y están relacionadas con alteraciones del sistema inmune., Body processes [G] - Immune system processes [G12]
 
 
ChiCTR1800020022: A multicenter, One-arm, Open, Prospective study for Low-dose Lenalidomide plus Rituximab (Laili) Regimen in the treatment of Elderly or Relapsed/Refractory B-cell non-Hodgkin's Lymphoma

Not yet recruiting
4
100
 
low dose of lenalidomide and rituximab
The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, self-financed
B-cell non-Hodgkin's lymphoma
 
 
2020-002507-19: Research into administration of lower dosed rituximab with an injection Onderzoek naar het toedienen van lagere doseringen rituximab via een injectie

Not yet recruiting
4
36
Europe
rituximab, Solution for injection, Concentrate for solution for infusion, MabThera, Rixathon
Sint Maartenskliniek, Sint Maartenskliniek
rheumatoid arthritis reumatoïde artritis, rheumatic disease reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
ReMIND, NCT01095172 / 2009-017066-23: RituxiMab INDuction in Renal Transplantation

Checkmark BTS 2016: ReMIND
Mar 2016 - Mar 2016: BTS 2016: ReMIND
Active, not recruiting
4
100
Europe
Rituximab, Mabthera, Tacrolimus, Advagraf, Adoport, Prograf, Mycophenylate mofetil, MMF, Cellcept, Hydrocortisone, Prednisolone
Guy's and St Thomas' NHS Foundation Trust, Astellas Pharma Europe Ltd.
Function of Renal Transplant
10/20
10/22
ChiCTR-IPR-16008527: Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controlled clinical study

Completed
4
180
 
oral CsA and glucosteroid ;intravenous RTX ;Intravenous cyclophosphamide and glucosteroid
Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine; Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine, Multi-center research funding of Shanghai Jiaotong University School of Medicine
Membranous nephropathy
 
 
ChiCTR1900020916: A Clinical study for low dose Dectabine + R-CHOP treat diffuse large B cells lymphoma

Recruiting
4
20
 
low dose Dac+R-CHOP ;R-CHOP
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Anhui province department of finance appropriation
Diffuse Large B Cells Lymphoma
 
 
2021-000710-42: Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC study) Onderzoek naar het effect van de COVID-vaccinatie bij patiënten die behandeld worden met rituximab (de RTX-COVAC studie).

Ongoing
4
270
Europe
COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca, Concentrate for solution for injection, Dispersion for injection, Suspension for injection, Comirnaty, COVID-19 Vaccine Moderna, COVID-19 Vaccine AstraZeneca
Sint Maartenskliniek, Sint Maartenskliniek
Rheumatoid arthritis Reumatoïde artritis, Rheumatic disease Reuma, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
ChiCTR2000035408: A randomized controlled study for rituximab in first-line treatment of newly diagnosed immune thrombocytopenia

Recruiting
4
60
 
Rituximab (Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29). ;Rituximab (Hanrikang) 100mg/ time once a week, administered 4 times (day 8, 15, 22 and 29). ;high-dose dexamethasone (HD-DXM), 40mg/d, iv for 4 days (day 1 to day 4), every 15 days, 2 to 4 cycles, until CR or the end of the study.
Henan Cancer Hospital; Henan Cancer Hospital, Jiangsu fosun pharmaceutical sales co. LTD
Idiopathic Thrombocytopenic Purpura
 
 
NCT04542629: Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

Not yet recruiting
4
140
NA
RiTUXimab Injection [Rituxan], KETOGENIC DIET, TRACE ELEMENTS, CORTICOSTEROID INJECTION
Assiut University
Refractory Epilepsy
08/21
08/22
ChiCTR1800017001: Precision Medicine Study about Drug Effect and Adverse Reaction of Rituximab in lymphonma Treatment Based on Metabonomics, Pharmacogenomics and Gut Microbiota.

Recruiting
4
200
 
none
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, National Natural Science Foundation of China (81730103,81573507), Hospital Pharmacy Fundation of Guangdong
B cell lymphoma
 
 
ChiCTR1900026380: Rituximab plus Lenalidomide in elderly untreated patients with DLBCL

Recruiting
4
60
 
Rituximab plus Lenalidomide
Anhui Provincial Cance Hospital; Anhui Provincial Cance Hospital, Self-collected
DLBCL
 
 
ChiCTR2000033540: Prospective Randomized Trial on Efficacy of Rituximab Combined Therapy and Supportive Therapy on Early-Stage Non-Nephrotic Primary Membranous Nephropathy

Recruiting
4
38
 
Rituximab 600mg iv, and supportive treatment ;Supportive treatment according to KDIGO guideline
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Self-supporting
Membranous Nephropathy
 
 
MAINTANCAVAS, NCT02749292: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

Terminated
4
115
US
Rituximab, Rituxan
Massachusetts General Hospital
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
01/22
01/22
NCT04518475: Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Recruiting
4
224
RoW
eltrombopag combining rituximab, TPO-R agonist & anti-CD20 antibody, eltrombopag, TPO-R agonist
Institute of Hematology & Blood Diseases Hospital, The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Nantong University
Primary Immune Thrombocytopenia (ITP)
02/22
08/22
NCT05191225: Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study

Recruiting
4
48
Europe
RiTUXimab Injection [Truxima]
Laida Cuevas Palomares
Non-Hodgkin's Lymphoma
03/22
12/22
ChiCTR2000040799: Prospective study of rituximab combined with low-dose hormone in the treatment of idiopathic membranous nephropathy

Recruiting
4
50
 
Rituximab
The First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital, Sun Yat-Sen University, self-raised
idiopathic membranous nephropathy
 
 
ChiCTR2000033337: R-BAC regimen in the treatment of relapsed and refractory diffuse large B-cell lymphoma

Not yet recruiting
4
50
 
Rituximab, Bendamustine combined with Cytarabine
Xiangya Second Hospital of Central South University; Xiangya Second Hospital of Central South University, Self-raised
Relapsed and refractory diffuse large B-cell lymphoma
 
 
ChiCTR2000036318: A prospective phase II multicenter clinical study of rituximab combined with local radiotherapy in the treatment of newly diagnosed early mucosa-associated lymphoid tissue lymphoma

Not yet recruiting
4
60
 
rituximab combined with local radiotherapy
Anhui Provincial Cance Hospital; Level of the institution：, Self-collected
mucosa-associated lymphoid tissue lymphoma
 
 
ChiCTR2300070327: Efficacy of novle prednisone-premedication R-CHOP protocol vs. standard R-CHOP regimen in the prevention of rituximab-related reactions in newly-diagnosed diffuse large B cell lymphoma: A multicenter randomized controlled study

Completed
4
88
 
prednisone-premedication R-CHOP protocol ;standard R-CHOP regimen
Jiujiang University Affiliated Hospital; Jiujiang University Affiliated Hospital, None
diffuse large B cell lymphoma
 
 
rituximab treatment for MN with T2DM, ChiCTR2000032523: Efficacy and safety of rituximab in the treatment of primary membranous nephropathy with type 2 diabetes mellitus: a single-center randomized controlled trial.

Not yet recruiting
4
80
 
rituximab ;tacrolimus
Xinqiao Hospital; Xinqiao Hospital, The science and technology innovation ability enhancement special project of The Army Medical University
membranous nephropathy
 
 
ChiCTR1900025744: Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial

Recruiting
4
60
 
Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg) ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750～3000mg/day)
The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The General Hospital of Chinese Peoples Liberation Army, funded by the National Natural Science Fundation of China (NO.81870662)
neuromyelitis optica spectrum disorder （NMOSD）
 
 
NCT02752815: Reduced Chemotherapy in Low Risk DLBCL

Active, not recruiting
4
290
RoW
Rituximab, Cyclophosphamide, Epirubicin, Vincristine, Prednisone
Ruijin Hospital
Diffuse Large B-cell Lymphoma
10/22
12/24
ChiCTR2000039456: A single arm and prospective clinical trial of zanubrutinib plus R-CHOP in untreated double expression diffuse large B-Cell Lymphoma with international prognostic index equal or greater than 2 scores

Recruiting
4
49
 
zanubrutinib plus R-CHOP
West China Hospital, Sichuan University; West China Hospital, Baiji Shenzhou Biotechnology Co., Ltd
double expressing diffuse large B-cell lymphoma
 
 
ChiCTR1900026382: Low dose rituximab driven by B cell count for nephrotic syndrome: a multi-center prospective cohort study

Completed
4
105
 
Rituximab
Jiangsu Province People's Hospital; Jiangsu Province People's Hospital, Jiangsu Province Kidney Disease Clinical Research Center program (BL 20100080)
nephrotic syndrome
 
 
ChiCTR2000030603: A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for glucocorticoid-dependent immune thrombocytopenia

Recruiting
4
390
 
treat with glucocorticoid ;treat with eltrombopag ;treat with rituximab ;treat with splenectomy ;treat with azathioprine ;treat with cyclosporine
The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University
Primary Immune Thrombocytopenia
 
 
 

Download Options